|
Orthologous residues
|
|
TICAM2 (human): S16‑p, TICAM2 (mouse): S14‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
THP1 (myeloid)
|
|
Cellular systems studied:
cell lines
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCE (human)
|
genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
LPS
|
|
|
|
increase
|
|
|
bisindolylmaleimide
|
LPS
|
|
|
inhibit treatment-induced increase
|
|
|